Aglaia

Get funding

Aglaia invests in oncology drug development companies.

Use:
Date closing: -
Amount: -
Industry focus: Health;
Total budget: -
Entity type: Venture Capital
Vertical focus: oncology
Website: https://aglaia-oncology.com/about-aglaia/

Status:
Open
Funding type:
Geographic focus:
Public/Private: Private
Stage focus:
Applicant target: Startup;

Add a Review Send question

Overview

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities

Funds

-Aglaia Oncology Fund II: active,

-Aglaia Oncology Growth Opportunity Fund: active,

-Aglaia Oncology Growth Opportunity Fund II: active,

-Aglaia Oncology Fund III: planned.

Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, of which 6 were founded by Aglaia. Aglaia Growth Fund(s) further invest in selected portfolio companies. The experienced team has been involved in the development of more than 100 oncology products. The continuous strategic and operational involvement of the team with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companies to clinical-stage companies. By doing so, Aglaia has de-risked and matured these companies up to the level at which they become attractive candidates for licensing, acquisition or IPO.

Portfolio: Merus, Modra, Mimetas, Sapreme.

Last updated on 2023-05-19 11:23